BALTIMORE, Aug. 29,
2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc.
(NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage
pharmaceutical company focused on the development and
commercialization of a novel synthetic THC analog, will host a
virtual roadshow webinar on Monday,
September 11, 2023 at 1:00 p.m.
Eastern Time.
Erez Aminov, Chief Executive
Officer of MIRA Pharmaceuticals, will present an overview of the
Company's growth strategy and operational roadmap. The webinar will
be accompanied by a presentation and followed by a
question-and-answer session, which can be accessed via the webcast
link or dial-in numbers below.
To access the webinar, please use the following information:
Date:
|
Monday, September 11,
2023
|
Time:
|
1:00 p.m. Eastern
Time
|
Dial-in
(U.S.):
|
1-877-269-7751
|
International
Dial-in:
|
1-201-389-0908
|
Webcast:
|
MIRA Virtual
Roadshow
|
A telephone replay will be available approximately three hours
after the call and will run through Monday,
October 9, 2023, by dialing 1-844-512-2921 from the U.S., or
1-412-317-6671 from international locations, and entering replay
pin number: 13740748. The replay can also be viewed through the
webinar webcast link above.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a
pre-clinical-stage pharmaceutical development company developing an
unscheduled novel synthetic THC analog. This novel compound is
currently under investigation for treating adult patients suffering
from anxiety and cognitive decline, often associated with
early-stage dementia. MIRA1a, if approved by the FDA, could mark a
significant advancement in addressing various neuropsychiatric,
inflammatory, and neurologic diseases and disorders. Based on
pre-clinical and animal studies conducted by the Company, the
Company believes that MIRA1a may enhance the therapeutic potential
for treating anxiety, cognitive decline, and neuropathic pain
without the side effects of plant-based THC. Furthermore, the
Company's studies indicate that MIRA1a may counteract the adverse
cognitive effects often seen with THC, thereby potentially
unmasking previously unseen positive therapeutic effects, such as
cognitive performance enhancement.
The U.S. Drug Enforcement Administration (DEA)'s scientific
review of MIRA1a concluded that MIRA1a would not be considered a
controlled substance or listed chemical under the Controlled
Substances Act (CSA) and its governing regulations.
Additional information about the Company is available
at: www.mirapharmaceuticals.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the Company's current expectations. These forward-looking
statements include, without limitation, references to the Company's
expectations regarding the closing of the public offering and its
anticipated use of net proceeds from the offering. These statements
are not guarantees of future performance and are subject to certain
risks, uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, risks and uncertainties related to the satisfaction
of customary closing conditions related to the public offering, or
factors that result in changes to the Company's anticipated use of
proceeds. These and other risks and uncertainties are described
more fully in the section captioned "Risk Factors" in the Company's
Registration Statement on Form S-1, as amended, related to the
public offering (SEC File No. File No. 333-273074). Forward-looking
statements contained in this announcement are made as of this date,
and the Company undertakes no duty to update such information
except as required under applicable law.
View original
content:https://www.prnewswire.com/news-releases/mira-pharmaceuticals-to-host-virtual-roadshow-webinar-on-monday-september-11-2023-at-100-pm-eastern-time-301912738.html
SOURCE MIRA Pharmaceuticals, Inc.